 | |
| Clinical data | |
|---|---|
| Other names | 4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate) |
| Routes of administration | By mouth[1] |
| Pharmacokinetic data | |
| Metabolites | Tropoflavin[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H16N2O6 |
| Molar mass | 368.345 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
R13 is asmall-moleculeflavonoid andorally active,potent, andselectiveagonist of thetropomyosin receptor kinase B (TrkB) – the mainsignaling receptor for theneurotrophinbrain-derived neurotrophic factor (BDNF) – which is under development for the potential treatment ofAlzheimer's disease.[1][2] It is astructural modification andprodrug oftropoflavin (7,8-DHF) with improved potency andpharmacokinetics, namelyoralbioavailability andduration.[1] The compound is a replacement for the earlier tropoflavin prodrugR7 and has similar properties to it.[1][3] It was developed because while R7 displayed a good drug profile in animal studies, it showed almost noconversion into tropoflavin in humanlivermicrosomes.[1] In contrast to R7, R13 is readilyhydrolyzed into tropoflavin in human liver microsomes.[1]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
